Questcor Pharmaceuticals, Inc. (Questcor), incorporated November 02, 1990, is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of innovative, acute care and critical care hospital/specialty pharmaceutical products. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.The company's primary product is H.P. Acthar Gel, an injectable drug used for the treatment of 19 indications including more »
When you look at the S&P 500’s most shorted stocks, all are cheap yet short investors continue to bet on lower prices. Therefore, I am looking at the most shorted stocks according to Bespoke Investment Group’s monthly list, to determine if any are a “buy.”
Short-Interest vs. Float
Shares Short (4/30)
Shares Short (3/30)
Blyth (NYSE: BTH)
5.32 more »
Questcor Pharmaceuticals (NASDAQ: QCOR) has faced the affects of bad press more than once in the past. The stock lost more than half of its value last year, after reports about its questionable marketing practices spurred a federal investigation. While that drop was extremely painful for long-term investors, it gave speculators and short-term traders an opportunity to make substantial profits, and let long-term investors add to their positions. The stock more »
With earnings season in full-swing, and with countless large moving stocks, I am looking at four companies that reported earnings on Wednesday that I believe are a “buy,” regardless of the stock’s initial reaction.
An Under-the-Radar Stock to Watch
Mueller Water Products (NYSE: MWA) saw gains of more than 13% after the company announced earnings that handily beat expectations. The company experienced sales growth of 12.6% year-over-year (yoy more »
Many believed that Q1 earnings would be the start of a larger trend higher that reversed the losses seen in shares of Questcor Pharmaceuticals (NASDAQ: QCOR) over the last year, but were those people ever wrong.
Questcor Pharmaceuticals is trading with losses of 9% immediately following its Q1 earnings report. For the quarter, Questcor grew 41% and posted revenue of $135 million and an EPS of $0.76 more »
The market for prescription and over-the-counter drugs is huge and hugely profitable. With the global trend of an aging population well underway, it is nearly inevitable that demand for prescription and non-prescription drugs will rise. While much is made in the media regarding the so-called “patent cliff” faced by the large drug makers, well-placed investments now will allow investors to reap double-digit gains for years to come. Investors who are more »
Have you ever been dumpster diving? I have--it is a great past time. One thing I've learned is that you never know what some people will throw away. Sometimes there is a reason it is being thrown out, while other times you find something that proves the old adage: one man's trash is another man's treasure.
This applies to the stock market as well. Many an investor more »
To say that William Leland Edwards of Palo Alto Investors invests heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »
Have you ever been dumpster diving? I have. It is a great past time. One thing I've learned is that you never know what some people will throw away. Sometimes there is a reason it is being thrown out. Other times you find something that proves the old adage: one man's trash is another man's treasure.
This applies to the stock market as well. Many an investor more »
To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »
Peter Lynch, one of the most successful investors in the world, managed to grow Fidelity Magellan Fund from $20 million to around $14 billion from 1977 to 1990. He has delivered an unmatched investment performance of a 29% annualized return. He advised investors to know what they own, and spent a lot of time identify good businesses with good management.
In his book, “One Up On Wall Street”, he laid more »
There is always something interesting happening in the Bio-Pharma sector due to a number of firms working on several new drugs. Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on developing RNA-based therapies. The company is currently working on Eteplirsen, a drug to cure Duchenne Muscular Dystrophy – it is a rare disease that mainly occurs in boys.
The disease is caused by a mutation in a gene, called the more »
A large downtrend is often a normal part of any stock’s life cycle. There are very few stocks that see massive runs higher that then don’t experience at least one 40% swing lower (i.e., Netflix, Green Mountain Coffee Roaster, Apple). This swoon can often create opportunity to repurchase the stock at a much cheaper price, as it usually realigns expectations with growth. Here, I am looking at more »
Yesterday, I published an article titled, “When Being Short Backfires!” So it's only appropriate to look at the other side of the trade. Strangely enough, this comes as one of my favorite companies of the last five years released guidance that simply left me speechless, providing the perfect example of when being long and optimistic backfires!
Staying Long & Optimistic Despite Obvious Problems
Stock options can induce fear in even the savviest of investors. Despite having the potential to mitigate risk and increase returns, the sheer magnitude and complexity of different strategies often force some investors astray. However, certain strategies are less imposing than they seem, and can be implemented into the common investor’s portfolio. Here are three limited-risk approaches you can execute with confidence.
Bull Call Spread
An effective strategy to more »
Some companies were happy to see the end of 2012. Questcor Pharmaceuticals (NASDAQ: QCOR) was one of them. The company had a terrible second half of the year, due to fears about insurance coverage and some bad press. The stock lost more than half of its value after reports came out about the suspect marketing practices of the company.
An investigation into the marketing practices of the company created significant more »
Earnings can dictate the direction of a stock for the following three months. Investors pay close attention to earnings and often make emotional decisions based on the performance of a stock post-earnings. However, the performance of a stock following earnings should never be the first line of research, rather the last. With that being said, I am looking at three stocks that I believe are a buy right now based more »
Put the blame on mame, boys, put the blame on mame ~ Rita Haywarth
Questcor Pharmaceuticals (NASDAQ: QCOR) can definitely put the blame on a lot of negative publicity - much of it false, malicious, or plain silly - for having lost almost 35% of its market capitalization in 2012, and for losing another nearly 4.5% of its value year-to-date.
This is funny because this is a company that has been beating more »
Rising earnings estimates and strong third quarter results, including a 28.2% positive earnings surprise, helped Intuitive Surgical (NASDAQ: ISRG) achieve a Zacks #1 Rank (Strong Buy) on Jan. 1. This pioneer of robotic surgery has delivered a positive earnings surprise in each of the last five quarters with an average of 13.7%.
Zacks expects that a number of procedures currently performed either in an open surgical more »
Selling people what they normally can have for free or for a nominal amount is a surefire way to make money. Think bottled water, especially the purified kind from the tap.
There aren't many products this blatantly marked up. One of the few that comes close is eyewear, as I discussed in October. At first glance, most drugs seem like they would fit this category as well, which explains more »
- Page 1 of 3